Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:00:29 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:IVBIY - INNOVENT BIOLOGICS INC UNSPON ADS EACH REP 4 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IVBIY - Qnot subscribed19.480.0302    24.14  18.6611:38:56Apr 0715 min RT 2¢

Recent Trades - All 2 today
Time ETExPriceChangeVolume
11:38:56Q14.51-4.9725
10:57:05Q19.600.125
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-07 20:00U:IVBIYNews ReleaseInnovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
2024-04-02 01:00U:IVBIYNews ReleaseInnovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
2024-03-26 20:00U:IVBIYNews ReleaseInnovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
2024-03-20 07:41U:IVBIYNews ReleaseInnovent Announces 2023 Annual Results and Business Updates
2024-03-18 20:00U:IVBIYNews ReleaseInnovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
2024-03-11 20:00U:IVBIYNews ReleaseInnovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
2024-03-06 22:41U:IVBIYNews ReleaseInnovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
2024-03-05 00:32U:IVBIYNews ReleaseInnovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
2024-02-29 19:00U:IVBIYNews ReleaseInnovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Ralpha/TSLP bispecific antibody) in Australia
2024-02-19 19:21U:IVBIYNews ReleaseInnovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
2024-02-07 03:35U:IVBIYNews ReleaseInnovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
2024-02-05 03:41U:IVBIYNews ReleaseInnovent Announces Retirement of CFO and Appointment of New CFO
2024-01-08 19:00U:IVBIYNews ReleaseInnovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
2024-01-01 19:00U:IVBIYNews ReleaseInnovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
2023-12-27 19:00U:IVBIYNews ReleaseInnovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
2023-12-26 19:00U:IVBIYNews ReleaseInnovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
2023-12-18 19:00U:IVBIYNews ReleaseInnovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
2023-12-17 19:00U:IVBIYNews ReleaseInnovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
2023-12-12 23:51U:IVBIYNews ReleaseInnovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT ‚ ® 's Seventh Indication and BYVASDA ‚ ®'s Eighth Indication
2023-12-06 20:00U:IVBIYNews ReleaseInnovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study